Dr. Nakakura - Neuroendocrine Tumors of Unknown Primary: Is the Primary Site Really Not Known?
- Exelixis and Ipsen Initiate Phase 3 Pivotal Trial (COSMIC-312) of Cabozantinib in Combination with Atezolizumab versus Sorafenib in Previously Untreated Advanced Hepatocellular Carcinoma
December 4, 2018 | Source: Bakersfield.com
- Two-pronged attack against lung cancer could overcome EGFR drug resistance
November 26, 2018 | Source: FierceBiotech.com
- The Pancreatic Cancer Collective awards $7 million in first-round "New Therapies Challenge" Grants
November 20, 2018 | Source: PRNewsWire.com